The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Novel therapies for high-risk MDS
Sangmin Lee, MD, Weill Cornell Medicine, New York City, NY, gives an overview of novel therapies for the treatment of high-risk myelodysplastic syndromes (MDS). Dr Lee comments on the need for therapies for patients who are relapsed/refractory to hypomethylating agents (HMAs), and highlights novel therapies such as sabatolimab, a TIM-3 inhibitor which is currently being investigated in a Phase II trial. Dr Lee also talks on the potential benefits of magrolimab and venetoclax, which are being investigated in combination with azacitidine. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
